Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Naudet

Showing results (1-10 of 185) with videos related to

Pageof 19
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|June 5, 2012
Can a 'true' effect be built on a 'wrong' model?Florian Naudet
Hepatology (Baltimore, Md.)|February 20, 2019
Letter to the Editor: No Baclofen for Alcohol Use Disorders Even More When Liver Disease Is Serious!Alain Braillon, Florian Naudet
The Lancet. Psychiatry|November 11, 2018
Baclofen and alcohol in FranceFlorian Naudet, Alain Braillon
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2022
Alcohol-related liver disease treatment and EBMAlain Braillon, Florian Naudet
Mayo Clinic Proceedings|October 5, 2020
Pharmacotherapies for Alcohol Use Disorder: Over Both Sides of the Atlantic OceanAlain Braillon, Florian Naudet
International Clinical Psychopharmacology|June 23, 2023
Severe methodological problems in a recent review and analysis of the association between lithium concentration in potable water and suicide ratesMartin Plöderl, Florian Naudet
BMJ (Clinical Research Ed.)|January 18, 2023
STROBE and pre-registration of observational studiesAlain Braillon, Florian Naudet
Journal of Affective Disorders|February 6, 2026
Recommendations for repeated dosings of ketamine/esketamine rest on an uncertain evidence base. Response toMartin Plöderl, Florian Naudet
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 30, 2017
Baclofen and alcohol use disorders: From miracle to mirageAlain Braillon, Florian Naudet
Journal of Psychopharmacology (Oxford, England)|May 3, 2023
Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effectsAlain Braillon, Florian Naudet
Pageof 19

Showing results (1-10 of 185) with videos related to

Sort By:
Pageof 19
The British Journal of Psychiatry : the Journal of Mental Science|June 5, 2012
Can a 'true' effect be built on a 'wrong' model?Florian Naudet
Hepatology (Baltimore, Md.)|February 20, 2019
Letter to the Editor: No Baclofen for Alcohol Use Disorders Even More When Liver Disease Is Serious!Alain Braillon, Florian Naudet
The Lancet. Psychiatry|November 11, 2018
Baclofen and alcohol in FranceFlorian Naudet, Alain Braillon
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2022
Alcohol-related liver disease treatment and EBMAlain Braillon, Florian Naudet
Mayo Clinic Proceedings|October 5, 2020
Pharmacotherapies for Alcohol Use Disorder: Over Both Sides of the Atlantic OceanAlain Braillon, Florian Naudet
International Clinical Psychopharmacology|June 23, 2023
Severe methodological problems in a recent review and analysis of the association between lithium concentration in potable water and suicide ratesMartin Plöderl, Florian Naudet
BMJ (Clinical Research Ed.)|January 18, 2023
STROBE and pre-registration of observational studiesAlain Braillon, Florian Naudet
Journal of Affective Disorders|February 6, 2026
Recommendations for repeated dosings of ketamine/esketamine rest on an uncertain evidence base. Response toMartin Plöderl, Florian Naudet
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 30, 2017
Baclofen and alcohol use disorders: From miracle to mirageAlain Braillon, Florian Naudet
Journal of Psychopharmacology (Oxford, England)|May 3, 2023
Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effectsAlain Braillon, Florian Naudet
Pageof 19